ZUG, Switzerland-Saturday 11 June 2022 [ AETOS Wire ]
Both studies met their primary endpoints with significantly higher
response than placebo after one month for both frown lines and crow’s
feet
Results showed rapid onset of action with median
response within two days (39% saw results on Day 1 for frown lines and
34% on Day 1 for crow’s feet)
Results also demonstrated long duration of action up to six months and high participant satisfaction
Treatment was well tolerated with all treatment-related adverse events mild-to-moderate and non-serious
(BUSINESS
WIRE) -- Galderma announced today at the Vegas Cosmetic Surgery &
Aesthetic Dermatology meeting, topline results from two phase III
clinical studies (NCT04249583, NCT04249687) demonstrating that
RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A,
improves both glabellar and lateral canthal lines with a rapid onset of
action and a long duration up to six months.1,2
Developed by
Galderma, RelabotulinumtoxinA is a highly-active, innovative,
complex-free, and ready-to-use liquid botulinum toxin A with a
proprietary strain and manufactured using a state-of-the-art, unique
process.1,3 RelabotulinumtoxinA is designed as a liquid, avoiding the
traditional requirement to reconstitute from powder, eliminating
variability, errors and risks associated with reconstitution, which
would be expected to improve the consistency of results. The READY
(RElabotulinumtoxin Aesthetic Development StudY) phase III clinical
program is composed of four phase III clinical trials which enrolled
more than 1,900 participants.
"We developed this innovative
neuromodulator to respond directly to the needs of healthcare
professionals and the expectations of patients who are looking for a
safe, effective, long-lasting treatment that offers consistency in
results for frown lines and crow’s feet, which can have a significant
impact on patients’ self-esteem and well-being. We are looking forward
to submitting the data to U.S. and global authorities as part of the
next step in bringing this potential, new treatment to patients.”
Baldo Scassellati Sforzolini, M.D.
Global Head of Research & Development
Galderma
Both
studies met their primary endpoint, demonstrating a significant
≥2-grade composite improvement (as assessed by both subject and
investigator) in glabellar line severity and lateral canthal line
severity vs. placebo at Month 1, with rapid onset of action and up to
six-month duration of action.
The first clinical study, READY-1,
was a multicenter, randomized, double-blind, placebo-controlled, phase
III trial of RelabotulinumtoxinA for the treatment of moderate-to-severe
glabellar lines (frown lines) in 300 participants followed for six
months.1 Results from READY-1 showed that RelabotulinumtoxinA
significantly reduced glabellar line severity and was well tolerated.1
READY-1
met its primary endpoint for participants with moderate-to-severe
glabellar lines – the response to RelabotulinumtoxinA was significantly
higher than placebo after one month (82.9% vs. 0%; P<0.001).1
In
the trial, RelabotulinumtoxinA had a rapid onset of effect (median 2
days, 39% of participants reported an effect on Day 1) and the effects
were long-lasting, persisting for up to six months. The median time to
return to baseline severity was >24 weeks (end of study).1
Participant
satisfaction with treatment was high for RelabotulinumtoxinA vs.
placebo. At Month 1, 97% of participants were satisfied with the outcome
of treatment and 86% remained satisfied at Month 6.1 Treated
participants were also highly satisfied with how natural they looked
(97% at Month 1, 88% at Month 6).1
The second study, READY-2, was
a multicenter randomized,double-blind, placebo-controlled, phase III
trial of RelabotulinumtoxinA for the treatment of moderate-to-severe
lateral canthal lines (crow’s feet).2 Results from the six-month study,
involving 303 participants, showed that treatment with
RelabotulinumtoxinA improved lateral canthal lines, with high
participant satisfaction and a rapid onset of effect.2
READY-2
met its primary endpoint with the response among those participants
receiving treatment significantly higher than placebo (51.8% vs. 1.4%,
P<0.001).2
The onset of effect was rapid (median 2 days, 34%
of participants reported onset of effect by Day 1) and the effect was
long-lasting, up to six months. The median time to return to baseline
severity was 173 days (24.7 weeks).2
Safety and tolerability profile
In
both studies, RelabotulinumtoxinA was well tolerated.1,2 All
treatment-related adverse events were mild-to-moderate, non-serious and
transient.1,2
In READY-1, 3.6% of treated participants (0%,
placebo) experienced a treatment-related adverse event; the most common
was headache.1 In READY-2, treatment-related adverse events occurred in
6.1% of treated participants (5.5%, placebo) and the most common was
injection-site bruising.2
About Galderma
Galderma is the
pure-play dermatology category leader, present in approximately 90
countries. We deliver an innovative, science-based portfolio of premium
flagship brands and services that spans the full spectrum of the
fast-growing dermatology market though Injectable Aesthetics,
Dermo-cosmetics and Therapeutic Dermatology. Since our foundation in
1981, we have dedicated our focus and passion to the human body’s
largest organ – the skin – meeting individual consumer and patient needs
with superior outcomes in partnership with healthcare professionals.
Because we understand that the skin we’re in shapes our lives, we are
advancing dermatology for every skin story. For more information:
www.galderma.com
References:
1. Shridharani, S., et al.
Treatment of moderate-to-severe glabellar lines with
RelabotulinumtoxinA, a new liquid botulinum toxin: Clinical efficacy and
safety results from the READY-1 Phase III trial. Poster presented at
Vegas Cosmetic Surgery & Aesthetic Dermatology 2022, Las Vegas, NV,
June 8-11, 2022
2. Ibrahim, SF, et al. Treatment of lateral
canthal lines with RelabotulinumtoxinA, a new liquid botulinum toxin:
Clinical efficacy and safety results from the READY-2 Phase III trial.
Poster presented at Vegas Cosmetic Surgery & Aesthetic Dermatology
2022, Las Vegas, NV, June 8-11, 2022.
3. Liljegren Sundberg, Å
and Ståhl, U. Relabotulinum toxin – a novel, high purity BoNT-A1 in
liquid formulation. Poster presented at TOXINS, virtual online event,
January 16-17, 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220610005026/en/
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Rachel Mooney
Global Franchise Communications
rachel.mooney@galderma.com
+41 76 261 64 41
Sébastien Cros
Corporate Communications Director
Sebastien.cros@galderma.com
+41 79 529 59 85